☆ 4.1 Article

Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial

INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)

Get Full Text
Add to Collection

Journal

INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 105, Issue 2, Pages 206-212

Publisher

SPRINGER JAPAN KK
DOI: 10.1007/s12185-016-2110-3

Keywords

ASP0113; Cytomegalovirus; DNA vaccine; Hematopoietic cell transplantation; Phase 2 open-label trial

Categories

Hematology

Funding

  1. Astellas Pharma Inc., Japan
  2. Astellas Pharma Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

ClinicalTrials.gov Identifier: NCT01903928.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.